Parker Waichman LLP

Canada Issues Warning On Antipsychotics In Pregnancy

Following an update in the United States earlier this year, Health Canada announced that it is advising healthcare professionals and consumers that the prescribing information for the entire class of antipsychotic drugs is being updated to include information on a pregnancy risk.The antispychotics covered by the update include Abilify, Risperdal, Seroquel, and Zyprexa, to name […]

Following an update in the United States earlier this year, Health Canada announced that it is advising healthcare professionals and consumers that the prescribing information for the entire class of antipsychotic drugs is being updated to include information on a pregnancy risk.The antispychotics covered by the update include <"https://www.yourlawyer.com/topics/overview/abilify">Abilify, <"https://www.yourlawyer.com/topics/overview/risperdal">Risperdal, <"https://www.yourlawyer.com/topics/overview/Seroquel-And-Cardiac-Death">Seroquel, and <"https://www.yourlawyer.com/topics/overview/zyprexa">Zyprexa, to name just a few.

Antipsychotic drugs are used to treat symptoms of psychiatric disorders such as schizophrenia and bipolar disorder.

The revised label will contain safety information on potential risks for abnormal muscle movements and withdrawal symptoms in newborns whose mothers were treated with these drugs during the third trimester of pregnancy, said Health Canada.

Earlier this year, we wrote that U.S. health regulators ordered that cautions be added to the labels of ALL antipsychotic drugs regarding their risk of abnormal muscle movements (extrapyramidal symptoms or EPS) and withdrawal syndromes in newborns when used in pregnancy. The new cautions apply to older and new generation antipsychotics, including Haldol, FazaClo, Fanapt, Clozaril, Risperdal, Zyprexa, Seroquel Abilify, Geodon, Invega, Loxitane, Moban, Navane, Orap, Saphris, Stelazine, Thorazine, and Symbyax, according to an alert from the U.S. Food & Drug Administration (FDA).

Health Canada warns women taking an antipsychotic and who are pregnant or thinking of becoming pregnant to speak with their physicians about treatment. Patients should not stop taking their medication without first speaking to a healthcare practitioner, as abruptly stopping an antipsychotic drug can cause serious adverse events.

Antipsychotic drugs are delivered in a variety of strengths and formulations—drops, liquid, tablets, and capsules taken by mouth, as a powder, solution for injection, or via suppository—and can be administered by healthcare professionals in a healthcare setting or taken by patients at home.

Health Canada notified Canadian antipsychotic drugs manufacturers—both typical and atypical versions—to update the Product Monographs to include this safety information. A list of approved antipsychotics in Canada can be accessed at (includes brand names, generic equivalents, and the active ingredient): http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2011/2011_78-eng.php. Hundreds of antipsychotic drugs are sold in Canada and this table provides drug names, but not the variations. Additional information, including the current Product Monograph, can be found by search of Health Canada’s Drug Product Database at http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php.

In the United States, according to the FDA, it identified 69 episodes of neonatal EPS or withdrawal in adverse event reports submitted to the agency through October 2008. Among the symptoms listed in the reports: agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder. Onset of symptoms ranged from birth to one month later, and the severity varied as well. The FDA indicated that some infants recovered within hours while others needed intensive care and prolonged hospitalization.

Health Canada noted that the abnormal muscle movements and withdrawal symptoms in newborns include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty in feeding, with symptoms ranging in severity. As in Canada, in some newborns, the symptoms could disappear within hours or days and not require specific treatment, while, in others, symptoms may be more severe and require medical attention.

The FDA updated the Pregnancy section of drug labels for the entire class of antipsychotic drugs to include consistent information about the potential risk for EPS and/or withdrawal symptoms in newborns whose mothers were treated with these drugs during the third trimester of pregnancy and provided a complete list of the antipsychotics included in this notification on its Website at: http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Awesome attorneys!
Glenn Rice
7 years ago
5 Star Reviews 150
Great staff extremely helpful and sympathetic to your needs
David Fritzman
5 years ago
5 Star Reviews 150
Excellent service
Cris Valdueza
6 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038